explore -WSS

explore

author：Wikipedia 2025-09-30 00:38:22 - browse：6558

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Readout LOUD podcast: Live from STAT Breakthrough Summit West

focus

WSS

HIV vaccine remains elusive. Immunologists keep trying new ideas

It's time to retire 'poor historian' from clinicians' vocabularies

Stanford president faces new allegations over 1999 paper

7 more heat

7 more heat

Big Tobacco's 'harm reduction': Is it for real, or a sham?

leisure time

explore

Wikipedia

Supreme Court strikes down use of affirmative action

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Medical records are filled with copy

NVIDIA and Google execs on the future of AI and drug discovery

United colonoscopy coverage change 'may cost lives,' doctors say

Texas Department of Public Safety speaks out on migrant abuse allegations

Medical leaders decry Supreme Court decision on affirmative action

Tocagen's brain cancer gene therapy trial continues. Investors worry

Apple is now the first public company to be valued at $3 trillion

Case highlights the risks of experimental stem cell therapy

hotspot

HIV vaccine remains elusive. Immunologists keep trying new ideas

Military medical care influenced by rank and race, new study finds

Bird flu: Don't repeat Covid's 'health versus the economy' framing

NVIDIA and Google execs on the future of AI and drug discovery

DeSantis talks Trump, trans issues and 'what wokeness is'

Vir antibody drug aimed at influenza A fails in clinical trial

focus

entertainment

focus

entertainment